Maritupirdine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description| | {{Short description|A drug under investigation for Alzheimer's disease}} | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = | | verifiedrevid = 477318123 | ||
| IUPAC_name = 1-(2-((2-(2,6-dimethylphenyl)thio)phenyl)piperazin-1-yl)ethanone | | IUPAC_name = 1-(2-((2-(2,6-dimethylphenyl)thio)phenyl)piperazin-1-yl)ethanone | ||
| image = AVN-101_Structure.svg | | image = AVN-101_Structure.svg | ||
}} | }} | ||
'''Maritupirdine''' (also known as '''AVN-101''') is | '''Maritupirdine''' (also known as '''AVN-101''') is a drug that has been under investigation for the treatment of [[Alzheimer's disease]]. It is a small molecule that acts as a [[serotonin receptor]] modulator, specifically targeting the [[5-HT6 receptor]]. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Maritupirdine functions primarily as a | Maritupirdine functions primarily as a [[5-HT6 receptor]] antagonist. The 5-HT6 receptor is a [[G protein-coupled receptor]] that is predominantly expressed in the [[central nervous system]], particularly in regions of the brain associated with cognition and memory, such as the [[cortex]] and the [[hippocampus]]. By blocking this receptor, maritupirdine is thought to enhance the release of [[neurotransmitters]] like [[acetylcholine]], [[dopamine]], and [[glutamate]], which are crucial for cognitive processes. | ||
==Clinical Development== | ==Clinical Development== | ||
Maritupirdine has | Maritupirdine has been evaluated in several clinical trials to assess its efficacy and safety in patients with [[Alzheimer's disease]]. These trials have focused on its potential to improve cognitive function and slow the progression of symptoms associated with the disease. However, as of the latest updates, maritupirdine has not yet received approval for clinical use. | ||
== | ==Pharmacokinetics== | ||
The | The pharmacokinetic profile of maritupirdine involves its absorption, distribution, metabolism, and excretion. It is administered orally and is known to cross the [[blood-brain barrier]], allowing it to exert its effects directly on the central nervous system. The drug is metabolized primarily in the liver and excreted through the kidneys. | ||
== | ==Potential Side Effects== | ||
As with many drugs affecting the central nervous system, maritupirdine may have side effects. These can include [[nausea]], [[headache]], [[dizziness]], and [[insomnia]]. The safety profile of maritupirdine continues to be evaluated in ongoing studies. | |||
==Research and Future Directions== | |||
Research into maritupirdine is ongoing, with scientists exploring its potential not only for [[Alzheimer's disease]] but also for other [[neurodegenerative disorders]] and [[cognitive impairments]]. The modulation of the 5-HT6 receptor remains a promising target for therapeutic intervention in various cognitive disorders. | |||
==Related Pages== | ==Related Pages== | ||
* [[Alzheimer's disease]] | * [[Alzheimer's disease]] | ||
* [[5-HT6 receptor]] | |||
* [[Serotonin receptor]] | * [[Serotonin receptor]] | ||
* [[ | * [[Neurotransmitter]] | ||
[[Category: | [[Category:Experimental drugs]] | ||
[[Category:Serotonin receptor antagonists]] | [[Category:Serotonin receptor antagonists]] | ||
[[Category:Drugs with no legal status]] | [[Category:Drugs with no legal status]] | ||
Latest revision as of 16:38, 5 March 2025
A drug under investigation for Alzheimer's disease
| Maritupirdine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Maritupirdine (also known as AVN-101) is a drug that has been under investigation for the treatment of Alzheimer's disease. It is a small molecule that acts as a serotonin receptor modulator, specifically targeting the 5-HT6 receptor.
Mechanism of Action[edit]
Maritupirdine functions primarily as a 5-HT6 receptor antagonist. The 5-HT6 receptor is a G protein-coupled receptor that is predominantly expressed in the central nervous system, particularly in regions of the brain associated with cognition and memory, such as the cortex and the hippocampus. By blocking this receptor, maritupirdine is thought to enhance the release of neurotransmitters like acetylcholine, dopamine, and glutamate, which are crucial for cognitive processes.
Clinical Development[edit]
Maritupirdine has been evaluated in several clinical trials to assess its efficacy and safety in patients with Alzheimer's disease. These trials have focused on its potential to improve cognitive function and slow the progression of symptoms associated with the disease. However, as of the latest updates, maritupirdine has not yet received approval for clinical use.
Pharmacokinetics[edit]
The pharmacokinetic profile of maritupirdine involves its absorption, distribution, metabolism, and excretion. It is administered orally and is known to cross the blood-brain barrier, allowing it to exert its effects directly on the central nervous system. The drug is metabolized primarily in the liver and excreted through the kidneys.
Potential Side Effects[edit]
As with many drugs affecting the central nervous system, maritupirdine may have side effects. These can include nausea, headache, dizziness, and insomnia. The safety profile of maritupirdine continues to be evaluated in ongoing studies.
Research and Future Directions[edit]
Research into maritupirdine is ongoing, with scientists exploring its potential not only for Alzheimer's disease but also for other neurodegenerative disorders and cognitive impairments. The modulation of the 5-HT6 receptor remains a promising target for therapeutic intervention in various cognitive disorders.
